Abstract:The malignant transformation of normal cells is driven by both genetic and epigenetic changes. With the advent of next-generation sequencing and large-scale international consortia, it is now possible to profile the genomes and epigenomes of thousands of primary tumors from nearly every cancer type. These studies clearly demonstrate that the dynamic regulation of DNA methylation is a critical epigenetic mechanism of cancer initiation, maintenance, and progression. Proper control of DNA methylation is not only crucial for regulating gene transcription and tissue-specific cellular functions, but its broader consequences include maintaining the integrity of the genome and modulating the immune response. Here, we describe the aberrant DNA methylation changes in human cancers and how they contribute to the disease phenotypes. Aside from CpG island promoter DNA hypermethylation-based gene silencing, human cancers also display gene body DNA hypomethylation that is also associated with downregulated gene expression. In addition, the implementation of whole genome bisulfite sequencing (WGBS) has unveiled DNA hypomethylation of large blocks of the genome, known as partially methylated domains (PMDs), as well as cancer-specific DNA methylation aberrancies at enhancers and super-enhancers. Integrating WGBS and DNA methylation array data with mutation, copy number, and gene expression data has allowed for the identification of novel tumor suppressor genes and candidate driver genes of the disease state. Finally, we highlight potential clinical implications of these changes in the context of prognostic and diagnostic biomarkers, as well as therapeutic targets. Mounting evidence shows that DNA methylation data are effective and highly-sensitive disease classifiers, not only from analyses of the primary tumor but also from tumor-derived, cell free DNA (cfDNA) in blood of cancer patients. These findings highlight the power of DNA methylation aberrancies in providing efficacious biomarkers for clinical utility in improving patient diagnostics and their reversal using DNA methylation inhibitors in cancer treatment may be key in surveillance, treatment, and quality of life for cancer patients.

Targeting DNA Methylation Machinery in Pediatric Solid Tumors

DNA Hypermethylation As a Chemotherapy Target.

Targeting DNA methyltransferases for cancer therapy

Progress Toward Epigenetic Targeted Therapies for Childhood Cancer

Technologies for Targeting DNA Methylation Modifications: Basic Mechanism and Potential Application in Cancer.

Dna Methyltransferases in Hematologic Malignancies

DNA Methyltransferases: Emerging Targets for the Discovery of Inhibitors As Potent Anticancer Drugs

DNA methyltransferase inhibitors in cancer: From pharmacology to translational studies

DNA Methyltransferases: A Novel Target for Prevention and Therapy

Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs

DNA Methylation: From Cancer Biology to Clinical Perspectives

DNA Methylation Targeting: The DNMT/HMT Crosstalk Challenge

The Role of DNA Methylation and DNA Methyltransferases in Cancer

DNA Methyltransferase Inhibitors: Catalysts for Antitumour Immune Responses

DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application

Emerging role of different DNA methyltransferases in the pathogenesis of cancer

DNA Methyltransferase Inhibitors and Their Therapeutic Potential

DNA Methyltransferase Inhibitors and Their Therapeutic Potential.

Systematic Characterization of DNA Methyltransferases Family in Tumor Progression and Antitumor Immunity

Mutations in DNA Methyltransferases and Demethylases

DNA Methylation Profiles in Cancer Diagnosis and Therapeutics